2024-04-01 2025-03-31 2025-03-31 false 14761429 ZOMBIE MOLECULE LTD 2025-05-16 false iso4217:GBP xbrli:pure 14761429 2024-03-31 14761429 2025-03-31 14761429 2024-04-01 2025-03-31 14761429 2023-03-26 14761429 2024-03-31 14761429 2023-03-27 2024-03-31 14761429 bus:SmallEntities 2024-04-01 2025-03-31 14761429 bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 14761429 bus:FullAccounts 2024-04-01 2025-03-31 14761429 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 14761429 core:WithinOneYear 2025-03-31 14761429 core:AfterOneYear 2025-03-31 14761429 core:WithinOneYear 2024-03-31 14761429 core:AfterOneYear 2024-03-31 14761429 core:ShareCapital 2025-03-31 14761429 core:SharePremium 2025-03-31 14761429 core:RevaluationReserve 2025-03-31 14761429 core:OtherReservesSubtotal 2025-03-31 14761429 core:RetainedEarningsAccumulatedLosses 2025-03-31 14761429 core:ShareCapital 2024-03-31 14761429 core:SharePremium 2024-03-31 14761429 core:RevaluationReserve 2024-03-31 14761429 core:OtherReservesSubtotal 2024-03-31 14761429 core:RetainedEarningsAccumulatedLosses 2024-03-31 14761429 core:LandBuildings 2025-03-31 14761429 core:PlantMachinery 2025-03-31 14761429 core:Vehicles 2025-03-31 14761429 core:FurnitureFittings 2025-03-31 14761429 core:OfficeEquipment 2025-03-31 14761429 core:NetGoodwill 2025-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2025-03-31 14761429 core:ListedExchangeTraded 2025-03-31 14761429 core:UnlistedNon-exchangeTraded 2025-03-31 14761429 core:LandBuildings 2024-03-31 14761429 core:PlantMachinery 2024-03-31 14761429 core:Vehicles 2024-03-31 14761429 core:FurnitureFittings 2024-03-31 14761429 core:OfficeEquipment 2024-03-31 14761429 core:NetGoodwill 2024-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2024-03-31 14761429 core:ListedExchangeTraded 2024-03-31 14761429 core:UnlistedNon-exchangeTraded 2024-03-31 14761429 core:LandBuildings 2024-04-01 2025-03-31 14761429 core:PlantMachinery 2024-04-01 2025-03-31 14761429 core:Vehicles 2024-04-01 2025-03-31 14761429 core:FurnitureFittings 2024-04-01 2025-03-31 14761429 core:OfficeEquipment 2024-04-01 2025-03-31 14761429 core:NetGoodwill 2024-04-01 2025-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 14761429 core:ListedExchangeTraded 2024-04-01 2025-03-31 14761429 core:UnlistedNon-exchangeTraded 2024-04-01 2025-03-31 14761429 core:MoreThanFiveYears 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments 2025-03-31 14761429 core:Non-currentFinancialInstruments 2024-03-31 14761429 dpl:CostSales 2024-04-01 2025-03-31 14761429 dpl:DistributionCosts 2024-04-01 2025-03-31 14761429 core:LandBuildings 2024-04-01 2025-03-31 14761429 core:PlantMachinery 2024-04-01 2025-03-31 14761429 core:Vehicles 2024-04-01 2025-03-31 14761429 core:FurnitureFittings 2024-04-01 2025-03-31 14761429 core:OfficeEquipment 2024-04-01 2025-03-31 14761429 dpl:AdministrativeExpenses 2024-04-01 2025-03-31 14761429 core:NetGoodwill 2024-04-01 2025-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2024-04-01 2025-03-31 14761429 dpl:GroupUndertakings 2024-04-01 2025-03-31 14761429 dpl:ParticipatingInterests 2024-04-01 2025-03-31 14761429 dpl:GroupUndertakings core:ListedExchangeTraded 2024-04-01 2025-03-31 14761429 core:ListedExchangeTraded 2024-04-01 2025-03-31 14761429 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2024-04-01 2025-03-31 14761429 core:UnlistedNon-exchangeTraded 2024-04-01 2025-03-31 14761429 dpl:CostSales 2023-03-27 2024-03-31 14761429 dpl:DistributionCosts 2023-03-27 2024-03-31 14761429 core:LandBuildings 2023-03-27 2024-03-31 14761429 core:PlantMachinery 2023-03-27 2024-03-31 14761429 core:Vehicles 2023-03-27 2024-03-31 14761429 core:FurnitureFittings 2023-03-27 2024-03-31 14761429 core:OfficeEquipment 2023-03-27 2024-03-31 14761429 dpl:AdministrativeExpenses 2023-03-27 2024-03-31 14761429 core:NetGoodwill 2023-03-27 2024-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2023-03-27 2024-03-31 14761429 dpl:GroupUndertakings 2023-03-27 2024-03-31 14761429 dpl:ParticipatingInterests 2023-03-27 2024-03-31 14761429 dpl:GroupUndertakings core:ListedExchangeTraded 2023-03-27 2024-03-31 14761429 core:ListedExchangeTraded 2023-03-27 2024-03-31 14761429 dpl:GroupUndertakings core:UnlistedNon-exchangeTraded 2023-03-27 2024-03-31 14761429 core:UnlistedNon-exchangeTraded 2023-03-27 2024-03-31 14761429 core:NetGoodwill 2025-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2025-03-31 14761429 core:LandBuildings 2025-03-31 14761429 core:PlantMachinery 2025-03-31 14761429 core:Vehicles 2025-03-31 14761429 core:FurnitureFittings 2025-03-31 14761429 core:OfficeEquipment 2025-03-31 14761429 core:AfterOneYear 2025-03-31 14761429 core:WithinOneYear 2025-03-31 14761429 core:ListedExchangeTraded 2025-03-31 14761429 core:UnlistedNon-exchangeTraded 2025-03-31 14761429 core:ShareCapital 2025-03-31 14761429 core:SharePremium 2025-03-31 14761429 core:RevaluationReserve 2025-03-31 14761429 core:OtherReservesSubtotal 2025-03-31 14761429 core:RetainedEarningsAccumulatedLosses 2025-03-31 14761429 core:NetGoodwill 2024-03-31 14761429 core:IntangibleAssetsOtherThanGoodwill 2024-03-31 14761429 core:LandBuildings 2024-03-31 14761429 core:PlantMachinery 2024-03-31 14761429 core:Vehicles 2024-03-31 14761429 core:FurnitureFittings 2024-03-31 14761429 core:OfficeEquipment 2024-03-31 14761429 core:AfterOneYear 2024-03-31 14761429 core:WithinOneYear 2024-03-31 14761429 core:ListedExchangeTraded 2024-03-31 14761429 core:UnlistedNon-exchangeTraded 2024-03-31 14761429 core:ShareCapital 2024-03-31 14761429 core:SharePremium 2024-03-31 14761429 core:RevaluationReserve 2024-03-31 14761429 core:OtherReservesSubtotal 2024-03-31 14761429 core:RetainedEarningsAccumulatedLosses 2024-03-31 14761429 core:NetGoodwill 2023-03-26 14761429 core:IntangibleAssetsOtherThanGoodwill 2023-03-26 14761429 core:LandBuildings 2023-03-26 14761429 core:PlantMachinery 2023-03-26 14761429 core:Vehicles 2023-03-26 14761429 core:FurnitureFittings 2023-03-26 14761429 core:OfficeEquipment 2023-03-26 14761429 core:AfterOneYear 2023-03-26 14761429 core:WithinOneYear 2023-03-26 14761429 core:ListedExchangeTraded 2023-03-26 14761429 core:UnlistedNon-exchangeTraded 2023-03-26 14761429 core:ShareCapital 2023-03-26 14761429 core:SharePremium 2023-03-26 14761429 core:RevaluationReserve 2023-03-26 14761429 core:OtherReservesSubtotal 2023-03-26 14761429 core:RetainedEarningsAccumulatedLosses 2023-03-26 14761429 core:AfterOneYear 2024-04-01 2025-03-31 14761429 core:WithinOneYear 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:CostValuation 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2024-04-01 2025-03-31 14761429 core:Non-currentFinancialInstruments core:CostValuation 2025-03-31 14761429 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2025-03-31 14761429 core:Non-currentFinancialInstruments core:CostValuation 2024-03-31 14761429 core:Non-currentFinancialInstruments core:AdditionsToInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:RevaluationsIncreaseDecreaseInInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:ImpairmentLossReversalProvisionsForImpairmentInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:AcquisitionsIncreaseInProvisionsForImpairmentInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:DisposalsDecreaseInProvisionsForImpairmentInvestments 2024-03-31 14761429 core:Non-currentFinancialInstruments core:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments 2024-03-31 14761429 bus:Director1 2024-04-01 2025-03-31 14761429 bus:Director2 2024-04-01 2025-03-31 14761429 bus:Director3 2024-04-01 2025-03-31

ZOMBIE MOLECULE LTD

Registered Number
14761429
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2025

ZOMBIE MOLECULE LTD
Company Information
for the year from 1 April 2024 to 31 March 2025

Directors | DAINES, Howard Frank
| DAINES, Mary Jean
| DAINES, Timothy Paul

Registered Address | 124 City Road
| London
| EC1V 2NX

Registered Number | 14761429 (England and Wales)

ZOMBIE MOLECULE LTD
Balance Sheet as at
31 March 2025

| Notes | 2025 |  | 2024
--- | --- | --- | --- | ---
|  | £ |  | £ |  | £ |  | £
Fixed assets |  |  |  |  |  |  |  |
Intangible assets | 3 |  |  | 25,146 |  |  |  | 6,500
Tangible assets | 4 |  |  | 1,769 |  |  |  | 1,720
|  |  |  | 26,915 |  |  |  | 8,220
Current assets |  |  |  |  |  |  |  |
Debtors | 5 | 19,080 |  |  |  | 13,200 |  |
Current asset investments | 6 | 23,004 |  |  |  | 5,489 |  |
Cash at bank and on hand |  | 33,353 |  |  |  | 9,097 |  |
|  | 75,437 |  |  |  | 27,786 |  |
Creditors amounts falling due within one year | 7 | (26,455) |  |  |  | (8,299) |  |
Net current assets (liabilities) |  |  |  | 48,982 |  |  |  | 19,487
Total assets less current liabilities |  |  |  | 75,897 |  |  |  | 27,707
Provisions for liabilities | 8 |  |  | (442) |  |  |  | (327)
Net assets |  |  |  | 75,455 |  |  |  | 27,380
Capital and reserves |  |  |  |  |  |  |  |
Called up share capital |  |  |  | 1 |  |  |  | 1
Profit and loss account |  |  |  | 75,454 |  |  |  | 27,379
Shareholders' funds |  |  |  | 75,455 |  |  |  | 27,380

- The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
- The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
- The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
- These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.
- The directors have chosen to not file a copy of the company’s profit and loss account under section 444 (5A) Companies Act 2006.

The financial statements were approved and authorised for issue by the Board of Directors on 16 May 2025, and are signed on its behalf by:
DAINES, Timothy Paul Director Registered Company No. 14761429

ZOMBIE MOLECULE LTD
Notes to the Financial Statements
for the year ended 31 March 2025

1. | Accounting policies
--- | ---

| Statutory information
--- | ---
| The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| Statement of compliance
--- | ---
| The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.

| Revenue from sale of goods
--- | ---
| Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.

| Employee benefits
--- | ---
| Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.

| Foreign currency translation
--- | ---
| Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

| Deferred tax
--- | ---
| Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.

| Intangible assets
--- | ---
| Intangible assets are stated at cost less accumulated amortisation and accumulated impairment losses. The assets are reviewed for impairment if the above factors indicate that the carrying amount may be impaired. Amortisation is included in 'administrative expenses' in the profit and loss account.

| Cryptocurrency assets
--- | ---
| Cryptocurrency assets (under IAS 38) are recorded as intangible assets and can be measured at either cost or revaluation. The company has elected to measure them at revaluation as there is now an active market across across many digital exchanges. Therefore, these are recognised at fair value. The assets are held for investment purposes and therefore cannot be recognised as stock as they are not being held for sale in the ordinary course of business.

| Tangible fixed assets and depreciation
--- | ---
| All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

|  | Reducing balance (%)
| Office Equipment | 25

| Investments
--- | ---
| Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

| Trade and other debtors
--- | ---
| Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

| Cash and cash equivalents
--- | ---
| Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.

| Financial instruments
--- | ---
| A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at transaction price and measured at amortised cost using the effective interest method. Where investments in non-derivative financial instruments are publicly traded, or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value through profit and loss. All other investments are subsequently measured at cost less impairment. Financial assets which are measured at cost or amortised cost are reviewed for objective evidence of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. All equity instruments, regardless of significance, and other financial assets that are individually significant, are assessed individually for impairment.

2. | Average number of employees
--- | ---

|  | 2025 |  | 2024
| Average number of employees during the year | 1 |  | 1

3. | Intangible assets
--- | ---

|  | Other |  | Total
--- | --- | --- | --- | ---
|  | £ |  | £
| Cost or valuation
| At 01 April 24 | 6,500 |  | 6,500
| Additions | 18,646 |  | 18,646
| At 31 March 25 | 25,146 |  | 25,146
| Net book value
| At 31 March 25 | 25,146 |  | 25,146
| At 31 March 24 | 6,500 |  | 6,500

4. | Tangible fixed assets
--- | ---

|  | Office Equipment |  | Total
--- | --- | --- | --- | ---
|  | £ |  | £
| Cost or valuation
| At 01 April 24 | 1,868 |  | 1,868
| Additions | 547 |  | 547
| At 31 March 25 | 2,415 |  | 2,415
| Depreciation and impairment
| At 01 April 24 | 148 |  | 148
| Charge for year | 498 |  | 498
| At 31 March 25 | 646 |  | 646
| Net book value
| At 31 March 25 | 1,769 |  | 1,769
| At 31 March 24 | 1,720 |  | 1,720

5. | Debtors: amounts due within one year
--- | ---

|  | 2025 |  | 2024
--- | --- | --- | --- | ---
|  | £ |  | £
| Trade debtors / trade receivables | 19,080 |  | 13,200
| Total | 19,080 |  | 13,200

6. | Current asset investments
--- | ---

7. | Creditors: amounts due within one year
--- | ---

|  | 2025 |  | 2024
--- | --- | --- | --- | ---
|  | £ |  | £
| Trade creditors / trade payables | 180 |  | -
| Taxation and social security | 25,810 |  | 7,325
| Other creditors | 465 |  | 473
| Accrued liabilities and deferred income | - |  | 501
| Total | 26,455 |  | 8,299

8. | Provisions for liabilities
--- | ---

|  | 2025 |  | 2024
--- | --- | --- | --- | ---
|  | £ |  | £
| Net deferred tax liability (asset) | 442 |  | 327
| Total | 442 |  | 327